Latest Repertoire Immune Medicines News & Updates
See the latest news and media coverage for Repertoire Immune Medicines. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing immune medicines
repertoire.com- Headquarters
- Cambridge, United States
- Founded year
- 2020
- Company type
- Private company
- Number of employees
- 80–200
Last updated
Latest news about Repertoire Immune Medicines
In short: Repertoire Immune Medicines secured FDA Fast Track Designation for RPTR-1-201 and entered a multi-billion dollar collaboration with Eli Lilly.
Company announcements
-
Repertoire Immune Medicines announces FDA Fast Track Designation for RPTR-1-201
The designation targets HLA-A*02:01-positive patients with unresectable or metastatic triple-negative breast cancer after standard therapies. RPTR-1-201, a TCR bispecific, is in Phase 1/2 trials.
-
Repertoire Immune Medicines shares exciting R&D achievement
The accomplishment highlights the agility and perseverance of their talented R&D group advancing cancer therapy urgently.
-
Repertoire Immune Medicines doses first participant in RPTR-1-201 trial
The Phase 1/2 trial evaluates safety, tolerability, and antitumor activity of the TCR bispecific therapy for advanced solid tumors, as monotherapy and with anti-PD-1.
-
Repertoire announces strategic collaboration with Lilly
The partnership uses Repertoire's DECODE platform to develop tolerizing therapies for autoimmune diseases. Lilly leads clinical development and commercialization.
Media coverage
-
Repertoire Immune Medicines Announces FDA Fast Track Designation for its Investigational Immune Medicine, RPTR-1-201
Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the U.S. Food and Drug...
-
Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors
Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the first participant has been...
-
Repertoire Immune Medicines Enters $1.9 Billion Collaboration with Eli Lilly to Develop Autoimmune Disease Therapies | PharmExec
The deal underscores a broader shift in autoimmune drug development toward therapies that aim to reprogram disease-driving immune responses at their source.
-
Repertoire and Lilly join hands on autoimmune disease therapies
Repertoire Immune Medicines has collaborated with Eli Lilly for the development of tolerising therapies to treat several autoimmune diseases.
Track Repertoire Immune Medicines and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Repertoire Immune Medicines competitors & trending companies
Browse news for competitors to Repertoire Immune Medicines and other trending companies.
Abcuro
Orna Therapeutics
Immutep
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable